Use of implantable cardioverter defibrillators after out-of-hospital cardiac arrest: a prospective follow-up study

Parkash, Ratika; Tang, Anthony; Wells, George; Blackburn, Josée; Stiell, Ian; Simpson, Christopher; Dorian, Paul; Yee, Raymond; Cameron, Doug; Connolly, Stuart; Birnie, David; Nichol, Graham
October 2004
CMAJ: Canadian Medical Association Journal;10/26/2004, Vol. 171 Issue 9, p1053
Academic Journal
Background: Survivors of out-of-hospital cardiac arrest are at high risk of recurrent arrests, many of which could be prevented with implantable cardioverter defibrillators (ICDs). We sought to determine the ICD insertion rate among survivors of out-of-hospital cardiac arrest and to determine factors associated with ICD implantation. Methods: The Ontario Prehospital Advanced Life Support (OPALS) study is a prospective, multiphase, before-after study assessing the effectiveness of prehospital interventions for people experiencing cardiac arrest, trauma or respiratory arrest in 19 Ontario communities. We linked OPALS data describing survivors of cardiac arrest with data from all defibrillator im-plantation centres in Ontario. Results: From January 1997 to April 2002, 454 patients in the OPALS study survived to hospital discharge after experiencing an out-of-hospital cardiac arrest. The mean age was 65 (standard deviation 14) years, 122 (26.9%) were women, 398 (87.7%) had a witnessed arrest, 372 (81.9%) had an initial rhythm of ventricular tachycardia or ventricular fibrillation (VT/VF), and 76 (16.7%) had asystole or another arrhythmia. The median cerebral performance category at discharge (range 1-5, 1 = normal) was 1. Only 58 (12.8%) of the 454 patients received an ICD. Patients with an initial rhythm of VT/VF were more likely than those with an initial rhythm of asystole or another rhythm to undergo device insertion (adjusted odds ratio [OR] 9.63, 95% confidence interval [CI] 1.31-71.50). Similarly, patients with a normal cerebral performance score were more likely than those with abnormal scores to undergo ICD insertion (adjusted OR 12.52, 95% CI 1.74-92.12). Interpretation: A minority of patients who survived cardiac arrest underwent ICD insertion. It is unclear whether this low usage rate reflects referral bias, selection bias by electrophysiologists, supply constraint or patient preference.


Related Articles

  • Implantable Defibrillators Reduce Death By 23% in Landmark Heart Failure Trial: NIH Study Indicates Need to More Aggressively Identify and Protect Patients at Risk for SCA.  // Journal of Cardiovascular Management;May/Jun2004, Vol. 15 Issue 3, p28 

    Reports on the results of the clinical trial for the implantable cardioverter-defibrillator therapy in people with heart failure in the U.S. Efficacy of the treatment in preventing sudden cardiac death; Safety profile in terms of general adverse events; Reason behind the underutilization of the...

  • Cameron Health Completes Enrollment in Pivotal FDA Clinical Study of the SICD( r) System.  // Biomedical Market Newsletter;5/9/2011, p507 

    The article reports that Cameron Health Inc. has completed enrollment in its pivotal FDA (U.S. Food & Drug Administration) clinical study of completely subcutaneous implantable defibrillator S-ICD System. Under the study, 330 patients were enrolled who were at risk for sudden cardiac arrest...

  • The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. O'Mahony, Constantinos; Lambiase, Pier D.; Quarta, Giovanni; Cardona, Montserrat; Calcagnino, Margherita; Tsovolas, Konstantinos; Al-Shaikh, Shereen; Rahman, Shafiqur M.; Arnous, Samer; Jones, Sue; McKenna, William; Elliott, Perry // Heart;Jan2012, Vol. 98 Issue 2, p116 

    Objective Implantable cardioverter defibrillators (ICDs) are routinely used to prevent sudden cardiac death (SCD) in selected hypertrophic cardiomyopathy (HCM) patients, but the determinants of device-related complications, therapies and long-term cardiovascular mortality in ICD recipients are...

  • Sudden cardiac death: opportunities for prevention. Morgan, J. M.; Cowan, J. C.; Camm, A. J.; McComb, J. M. // Heart;Jun2006, Vol. 92 Issue 6, p721 

    The evidence base for implantable cardioverter-defibrillator (ICD) therapy requires expansion of guidance/indications to allow UK physicians to treat a broader range of patients. The ICD clinical consultees to the National Institute for Health and Clinical Excellence (NICE) review current...

  • Cardiac implantable electronic devices in end-stage renal disease patients: preservation of central venous circulation. Lopera, Gustavo; Beathard, Gerald; Exaire, Jose; Carrillo, Roger // Journal of Interventional Cardiac Electrophysiology;Jun2012, Vol. 34 Issue 1, p101 

    The article offers recommendations for the use of implantable cardioverter-defibrillator (ICD) therapy for primary and secondary prevention of sudden cardiac death (SCD) in end-stage renal disease (ESRD) patients. It suggests offering epicardial or subcutaneous cardiac implantable electronic...

  • Single-chamber ICD, single-zone therapy in primary and secondary prevention patients: the simpler the better? González-Enríquez, S.; Rodríguez-Entem, F.; Expósito, V.; Castrillo-Bustamante, C.; Canteli, A.; Solloso, A.; Madrazo, I.; Olalla, J. // Journal of Interventional Cardiac Electrophysiology;Dec2012, Vol. 35 Issue 3, p343 

    Background: It is now well established that implantable cardioverter defibrillator (ICD) implantation reduces mortality in patients at increased risk of sudden cardiac death. However, the best programming parameters remain controversial. Our traditional policy has followed a simple approach in...

  • Study: 'real value outcomes, cost data involved in ICD use. Stommen, Jim // Medical Device Daily;5/7/2008, Vol. 12 Issue 89, p1 

    The article discusses research being done on the cost of implantable cardioverter defibrillators (ICD) for prevention of sudden cardiac arrest (SCA) and death in elderly patients. It references a study by Peter Groeneveld et al, published in the April 2007 issue of "Heart Rhythm." The...

  • Boston Scientific gets CE mark for Confient ICD to treat SCD.  // Medical Device Daily;10/12/2007, Vol. 11 Issue 196, p1 

    The article reports that Boston Scientific's Confient implantable cardioverter-defibrillator (ICD), a cardiac rhythm management device to treat sudden cardiac death (SCD), has received the CE-mark approval. The device has an AV Search Hysteresis feature designed to reduce unnecessary right...

  • Implantable cardioverter defibrillators work -- so why aren't we using them? Simpson, Christopher S. // CMAJ: Canadian Medical Association Journal Supplement;7/3/2007, Vol. 177 Issue 1, p49 

    The author comments on a study on implantable cardioverter defibrillators, a device used to reduce the death rate among survivors of cardiac arrest, conducted by D. H. Birnie and colleagues. The authors of the study found that the implantation rate of the device into survivors of sudden cardiac...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics